Acorda Therapeutics, Inc. (ACOR) Analysts See $0.33 EPS

April 20, 2018 - By Clifton Ray

Acorda Therapeutics, Inc. (NASDAQ:ACOR) LogoInvestors sentiment decreased to 0.99 in Q4 2017. Its down 0.23, from 1.22 in 2017Q3. It is negative, as 24 investors sold Acorda Therapeutics, Inc. shares while 46 reduced holdings. 23 funds opened positions while 46 raised stakes. 48.17 million shares or 6.13% less from 51.31 million shares in 2017Q3 were reported.
Proshare Advisors Ltd Liability owns 33,040 shares. Acadian Asset Mngmt Ltd Com owns 25,027 shares. Cornerstone Mgmt Ltd Llc stated it has 0% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). 64,789 are held by Bancorporation Of America De. The Massachusetts-based Martingale Asset Mgmt Ltd Partnership has invested 0.01% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Balyasny Asset Mgmt invested 0% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Wells Fargo & Mn holds 0% or 95,637 shares in its portfolio. New York-based Ny State Teachers Retirement has invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Texas-based Employees Retirement Sys Of Texas has invested 0.01% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). 3.45M are owned by Partner Fund Mgmt Limited Partnership. 5,587 are owned by Riverhead Capital Limited Liability Com. Art Advisors Ltd Liability Co holds 0.05% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 47,748 shares. D E Shaw & Com Incorporated has 571,767 shares for 0.02% of their portfolio. Stratos Wealth Prtn accumulated 170 shares. Schwab Charles Inv Management Incorporated accumulated 302,836 shares or 0.01% of the stock.

Since January 18, 2018, it had 0 insider purchases, and 2 insider sales for $1.81 million activity. Wasman Jane also sold $952,319 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) on Friday, January 19.

Analysts expect Acorda Therapeutics, Inc. (NASDAQ:ACOR) to report $0.33 EPS on May, 2 before the open.They anticipate $0.74 EPS change or 180.49 % from last quarter’s $-0.41 EPS. ACOR’s profit would be $15.49M giving it 17.61 P/E if the $0.33 EPS is correct. After having $0.45 EPS previously, Acorda Therapeutics, Inc.’s analysts see -26.67 % EPS growth. The stock decreased 0.64% or $0.15 during the last trading session, reaching $23.25. About 79,306 shares traded. Acorda Therapeutics, Inc. (NASDAQ:ACOR) has declined 10.61% since April 20, 2017 and is downtrending. It has underperformed by 22.16% the S&P500.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Ratings Coverage

Among 10 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Acorda Therapeutics had 20 analyst reports since October 31, 2017 according to SRatingsIntel. The firm earned “Hold” rating on Wednesday, January 31 by Janney Capital. Stifel Nicolaus maintained it with “Buy” rating and $26.0 target in Tuesday, October 31 report. The company was maintained on Monday, April 2 by H.C. Wainwright. The firm earned “Hold” rating on Wednesday, November 15 by Cantor Fitzgerald. The firm has “Underperform” rating given on Thursday, November 16 by Raymond James. The stock has “Hold” rating by Cantor Fitzgerald on Thursday, March 29. The stock has “Hold” rating by Jefferies on Wednesday, November 15. The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) has “Buy” rating given on Wednesday, January 17 by H.C. Wainwright. The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) earned “Hold” rating by Goldman Sachs on Wednesday, February 7. The rating was initiated by Piper Jaffray with “Hold” on Tuesday, November 28.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company has market cap of $1.09 billion. The firm markets Ampyra , an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It currently has negative earnings. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.